Active, not recruitingPhase 2NCT05007093
Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib
Studying Differentiated thyroid carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Yansong Lin
- Intervention
- Anlotinib hydrochloride(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2020 – 2025
Study locations (1)
- Peking Union Medical College Hospital, Beijing, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05007093 on ClinicalTrials.govOther trials for Differentiated thyroid carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07068542Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid CancerZhejiang Provincial People's Hospital
- RECRUITINGPHASE3NCT06860971A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid CarcinomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE2NCT06440850Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationCity of Hope Medical Center
- RECRUITINGPHASE2NCT06359847Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid CancerBeijing Scitech-Mq Pharmaceuticals Limited
- ACTIVE NOT RECRUITINGNANCT06422702The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid CancerHarbin Medical University
- RECRUITINGNCT05994365Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid CarcinomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- ACTIVE NOT RECRUITINGNCT04970134Spanish Study for Molecular Characterization of Thyroid CarcinomaGrupo Español de Tratamiento de Tumores de Cabeza y Cuello
- ACTIVE NOT RECRUITINGNCT02185560Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With SorafenibBayer